ClinicalTrials.gg
Active, not recruitingNCT06346392Updated Oct 15, 2026

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

A Phase 3 interventional study of AZD0901 and AZD0901 in Gastric Cancer and Gastroesophageal Junction Cancer, sponsored by AstraZeneca. Active, not recruiting at 158 sites in 19 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
594
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Stomach Neoplasms by AstraZeneca — 10 open to participants now, 18 under way, 3 of them phase 3. Stomach Neoplasms · AstraZeneca.

Enrollment
5th of 27
594 · median 124
Started
2024
with 1 other
Phase 3
4 of 30
2 open now
Primary completion
2026-05
later than 2 of 17 live
Registered
22nd of 30
by date

Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 3, reaches primary completion later than 2 of the 17 other live ones, and was the 22nd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

10 of the 30 studies in Stomach Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Stomach Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

Read the detailed description

This is a Phase III, multi-center, open-label, sponsor-blinded, randomized, global study to assess the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as the 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2, and the clinical performance of the investigational IVD. As part of this combined approach, the efficacy analyses from this study will also provide the basis to evaluate the clinical performance of Ventana CLDN18.2 assay as an IVD device for the identification of patients with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2 who may benefit from AZD0901.

03

Conditions studied

  • Gastric Cancer
  • Gastroesophageal Junction Cancer

Browse trials for

Keywords

  • Gastric cancer
  • Gastroesophageal junction cancer
  • Phase III
  • Claudin 18.2
  • AZD0901
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed prior to any study procedure.
  2. Participant must be at least 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.
  3. confirmed unresectable, locally advanced or adenocarcinoma of gastric, GEJ, or distal esophagus (distal third of the esophagus) and the following requirement:

    (a) Participants with positive CLDN18.2 expression from archival tumor collected within past 24 months or from a fresh .

  4. Disease progression on or after at least one (LoT) for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease.
  5. Must have at least one measurable or evaluable lesion assessed by the Investigator based on 1.1.
  6. performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
  7. Predicted of ≥ 12 weeks.
  8. Adequate organ and bone marrow function
  9. Body weight of ≥ 35 kg.
  10. Sex and Requirements

Exclusion criteria

Exclusion Criteria:

  1. Participants with known positive status as defined as IHC 3+ or IHC 2+/ISH + (Cases with HER2: CEP17 ratio ≥ 2 or an average HER2 copy number ≥ 6.0 signals/cell are considered positive by ISH). Participants must undergo local (or have had) HER2 testing by IHC/ISH, and the most recent result of HER2 status will be used to determine the eligibility.
  2. Participant has significant or unstable gastric bleeding and/or untreated gastric ulcers.
  3. or CNS pathology including: epilepsy, seizures or aphasia within 3 months prior to consent, severe brain injury, dementia, Parkinson's disease, neurodegenerative diseases, cerebellar disease, severe uncontrolled mental illness, psychosis, CNS involvement of diseases.
  4. Participant has known corneal disease (eg, active keratitis or corneal ulcerations).
  5. Persistent toxicities ( Grade ≥ 2) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss).
  6. Prior exposure to any ADC with MMAE payload or any CLDN18.2 targeting treatment other than naked monoclonal antibody (eg, CLDN18.2 targeting CAR-T cell therapy, multi-specific antibody including targeting CLDN18.2, etc).
  7. History of thromboembolic events:

    1. Participants with venous thromboembolism within the past 6 months prior to randomization: participants with venous port or catheter thrombosis or superficial venous thrombus that do not require treatment or are stable on treatment with anticoagulants are excepted
    2. History of arterial thromboembolism within the past 12 months prior to randomization
  8. As judged by the Investigator, any evidence of diseases which in the Investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
594 participants (actual)

Study arms

  • Experimental
    AZD0901 arm 1

    Participants in the AZD0901 arm 1 will receive AZD0901 dose level 1 intravenous infusion treatment.

    Drug: AZD0901

  • Experimental
    AZD0901 Arm 2

    Participants in the AZD0901 arm 2 will receive AZD0901 dose level 2 intravenous infusion treatment. (Enrolment was closed)

    Drug: AZD0901

  • Active comparator
    Investigator's choice arm

    Participants in the Investigator's choice arm will receive a regimen of Investigator's choice, including regionally accepted chemotherapies or targeted therapies.

    Drug: Ramucirumab+ paclitaxel · Drug: Paclitaxel · Drug: Docetaxel · Drug: Irinotecan · Drug: TAS-102 · Drug: Apatinib

Interventions

  • Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV

    Also known as: Sonesitatug Vedotin

  • Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV (Enrolment was closed)

    Also known as: Sonesitatug Vedotin

  • DrugRamucirumab+ paclitaxel

    Drug pages: Ramucirumab · Paclitaxel

    Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W

  • Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)

  • Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)

  • Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W

  • DrugTAS-102

    TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)

  • Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) in all randomized participants

    The analysis will include all randomized participants. All events will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy.

    Time frame: From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 3 years).

  2. Overall Survival (OS) for 3L+ participants

    The analysis will include all randomized participants who had at least 2 prior lines of systemic therapy. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy.

    Time frame: From date of first dose/randomisation until the date of death due to any cause (approximately 3 years).

Secondary outcomes

  1. OS in all randomized participants

    The analysis will include all randomized participants. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy.

    Time frame: From date of first dose/randomisation until the date of death due to any cause (approximately 3 years).

  2. PFS for 3L+ participants

    The analysis will include all randomized participants who had at least 2 prior lines of systemic therapy. All events will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy.

    Time frame: From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 3 years).

  3. Objective Response Rate (ORR) in all randomized participants

    ORR is defined as the proportion of participants with at least one visit response of confirmed CR or confirmed PR, as determined by BICR per RECIST 1.1.

    Time frame: From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 3 years).

  4. ORR for 3L+ participants

    The analysis will include all randomized participants who had at least 2 prior lines of systemic therapy, with measurable disease at baseline

    Time frame: From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 3 years).

  5. Duration of Response (DoR) in all randomized participants

    The analysis will include all randomized participants with measurable disease at baseline who have a confirmed response. All events after achieving confirmed response will be included, regardless of whether the participant withdraws from therapy, receives another anticancer therapy or clinically progresses prior to RECIST 1.1.

    Time frame: From the date of first documented confirmed response until date of documented progression (approximately 3 years).

  6. Serum concentrations of AZD0901, total antibody and MMAE

    To characterise the PK of AZD0901 in participants.

    Time frame: From date of first dose of AZD0901 up until 30 days post AZD0901 discontinuation.

  7. Status of ADA to AZD0901

    To determine the immunogenicity of AZD0901 in participants.

    Time frame: From date of first dose of AZD0901 up until 30 days post AZD0901 discontinuation.

  8. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]. Changes from baseline in vital signs, clinical laboratory results, and ECGs

    To assess the safety and tolerability of AZD0901 as compared with Investigator's choice of therapy in all randomized participants who have received at least one dose of study intervention

    Time frame: From start through 30 days post treatment completion and follow up for 90 days.

  9. PK parameters (such as peak concentration, as data allow) of AZD0901, total antibody and MMAE

    To characterise the PK of AZD0901 in participants.

    Time frame: From date of first dose of AZD0901 up until 30 days post AZD0901 discontinuation.

  10. PK parameters (such as trough concentration, as data allow) of AZD0901, total antibody and MMAE

    To characterise the PK of AZD0901 in participants.

    Time frame: From date of first dose of AZD0901 up until 30 days post AZD0901 discontinuation.

  11. Prevalence and incidence of ADA to AZD0901

    To determine the immunogenicity of AZD0901 in participants.

    Time frame: From date of first dose of AZD0901 up until 30 days post AZD0901 discontinuation.

  12. Titer of ADA to AZD0901

    To determine the immunogenicity of AZD0901 in participants.

    Time frame: From date of first dose of AZD0901 up until 30 days post AZD0901 discontinuation.

07

Study locations

158 sites
  • Research Site
    Mobile, Alabama 36604, United States
  • Research Site
    Tucson, Arizona 85719, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Irvine, California 92618, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Los Angeles, California 90089, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Boise, Idaho 83712, United States
  • Research Site
    Lexington, Kentucky 40536, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Ann Arbor, Michigan 48106, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    York, Pennsylvania 17403, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Fredericksburg, Virginia 22408, United States
  • Research Site
    Olympia, Washington 98502, United States
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    São Paulo, 05652-900, Brazil
  • Research Site
    Vitória, 29043-272, Brazil
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
  • Research Site
    London, Ontario N6C 2R5, Canada
  • Research Site
    North York, Ontario M2K 1E1, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H3G 1A4, Canada
  • Research Site
    Beijing, 100210, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chengdu, 610042, China
  • Research Site
    Fuzhou, 350001, China
  • Research Site
    Fuzhou, 350014, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, 510655, China
  • Research Site
    Guangzhou, 510700, China
  • Research Site
    Hangzhou, 310020, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Hefei, 230022, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Jining, 272029, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Lishui, 323000, China
  • Research Site
    Nanjing, 210008, China
  • Research Site
    Qingdao, 266034, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Shijiazhuang, 050011, China
  • Research Site
    Suzhou, 215004, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Wuhan, 430000, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Yinchuan, 750004, China
  • Research Site
    Zhengzhou, 450003, China
  • Research Site
    Besançon, 25030, France
  • Research Site
    Brest, 29200, France
  • Research Site
    Lille, 59037, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Nantes, 44000, France
  • Research Site
    Berlin, 10249, Germany
  • Research Site
    Berlin, 13353, Germany
  • Research Site
    Frankfurt, 60488, Germany
  • Research Site
    Göttingen, 37075, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Heilbronn, 74078, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Marburg, 35043, Germany
  • Research Site
    Moers, 47441, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Hong Kong, 150001, Hong Kong
  • Research Site
    Hong Kong, 999077, Hong Kong
  • Research Site
    Ahmedabad, 380015, India
  • Research Site
    Hyderabad, 500032, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    New Delhi, 110085, India
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Milan, 20162, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Pisa, 56100, Italy
  • Research Site
    Vicenza, 36100, Italy
  • Research Site
    Fukuoka, 812-8582, Japan

Showing the first 100 of 158 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036. PubMed 40341124 ↗
  • Xu G, Liu W, Wang Y, Wei X, Liu F, He Y, Zhang L, Song Q, Li Z, Wang C, Xu R, Chen B. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep Med. 2024 Sep 17;5(9):101710. doi: 10.1016/j.xcrm.2024.101710. Epub 2024 Sep 3. PubMed 39232496 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in May 2026, 26 months.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 26 months is below that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Apr 4, 2024
StartActual
Mar 4, 2024
Primary completionActual
May 31, 2026
CompletionEst.
Oct 14, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06346392
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
Mar 4, 2024
Primary completion
May 31, 2026
Completion
Oct 14, 2026 (estimated)
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonesitatug vedotin

Start the discussion